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1. Clinical research
Clinical research may be defined as the research in which an investigator directly deals with 
human subjects or on material of human origin. It includes mechanisms of human disease, 
therapeutic interventions, development of new technologies, epidemiologic and behavioral 
studies, and outcomes and health services research. Types of clinical research may be clas-
sified as retrospective/prospective that refers to the time of data collection. In prospective 
studies, the data are collected after the objectives are set. On the other hand, in retrospective 
studies, the data are collected before the objectives are set. Another classification is cohort/
cross-sectional studies. In cohort studies, the subjects are followed over time. On the other 
hand, in cross-sectional study, the subjects are examined at one point of time, e.g., prevalence 
of a disease [1].
1.1. Types of clinical research
1. Case reports
2. Observational studies: Data are collected for a set of patients without randomization.
3. Clinical trial: A prospective study evaluating the effect and value of intervention(s) in hu-
man subjects under pre-specified settings.
Clinical trials are considered the heart of all medical advances and the “Gold Standard” of 
clinical research. They are the most definitive tool for evaluation of the applicability of clinical 
research with the potential to improve the quality of health care and control costs. In other 
words, they bridge the gap between basic science and improved human health, as they inves-
tigate new ways to prevent, detect, or treat diseases or to improve the quality of life [2].
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Single center/multi-center trials: Multicenter trials enhance generalizability of the results. In 
multicenter studies, the use of a central lab makes data handling easier because there is only 
one set of reference ranges.
2. Non-comparative/comparative design
Noncomparative design is usually used to assess a treatment’s safety and tolerability and 
also in some therapeutic confirmatory studies if long-term safety data are required.
Comparative design is used when comparing treatments: controlled clinical trials groups are 
studied and contrasts made between groups. Different types of controls include: Historical/
Concurrent: Concurrent controls include placebo and active control (standard therapy or use 
another new therapy) or “sham” treatment control, e.g., sham surgery or acupuncture. The 
two most commonly used designs are [3]:
1. Cross-over: Each subject receives one treatment and then (after a wash out period) crosses 
over to receive the other treatment. The individual subject variability is minimized, hence 
the need for less number of subjects. This design should include an adequate wash out pe-
riod to ensure baseline status before giving the second treatment, the diseases in question 
must be stable; otherwise, it will not be considered ethical.
2. Parallel-group: Each subject receives only one of the study treatments for a predetermined 
period, individual subject variability must be taken into account, hence the need for a 
larger number of subjects [4].
2.1. Selection criteria: Inclusion and exclusion criteria
Selection criteria define which subjects to include and which to exclude. The intension is to 
identify the appropriate participants in a tightly defined population, based on factors as age, 
gender, the type and stage of the disease, previous treatment history, and other medical con-
ditions. Examples of exclusion criteria include concomitant therapy that may affect the course 
of the disease or may lead to drug interactions, women of child bearing potential, pregnant 
women, nursing mothers, and subjects who cannot comply with protocol (alcoholics or drug 
users).
3. Research bias
Selection/allocation bias occurs when researcher knows which with the possibility of being 
tempted to give the treatment under investigation either to subjects who had failed on previ-
ous therapy or to those who they think will do well. To eliminate selection bias, studies are 
conducted on a randomized fashion.
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Observer bias is when the investigator knows which treatment a study subject is taking with 
the possibility that subjects taking a new treatment may be over-scored. To eliminate observer 
bias, studies are conducted blind [5].
4. Randomization and blinding
Randomization: A process based on allocation of subjects to treatment groups by chance, 
aiming at removing the potential bias in treatment assignment whether conscious or subcon-
scious. This will greatly enhance the validity of the trial.
Blinding is when the investigator and/or the study subject do not know which subject is tak-
ing which treatment. The investigator, the participant, and sometimes even the evaluator are 
all kept unaware (blinded) of the outcomes of the trial.
1. Single-blinded study: either the investigator or the subject tested is blinded to the interven-
tion allocation.
2. Double-blinded study: both the investigator and the subject tested are unaware about of 
the intervention allocation.
3. Triple-blinded study: even the evaluator is also not aware of the process.
In emergencies and life threatening situations for participants, unblinding can be done.
Standard operating procedures (SOPs) ensure that the specific tasks in the trial are carried 
out in a consistent manner. Topics for SOPs for investigators:
1. Ethics: initial and continuing review by ethics committees, informed consent, consent 
forms, and information sheets
2. Study setup: review of investigator brochures, protocols, protocol amendments, CRFs, and 
agreements (e.g., responsibility, financial, confidential, and insurance/indemnity agreement)
5. Basic documents and materials of clinical trials
5.1. Protocol
The protocol is a written agreement between investigators, participants, and the scientific 
community. The protocol must inform (study staff) about how the study treatments will be 
assigned, how the subjects are to be treated, and what assessments are to be performed. It is 
the reference comprehensive operational manual that describes who is conducting the trial, 
who is sponsoring it, where is it to be conducted, and on whom it will be conducted, what 
is being tested?, why is this research needed, what are the risks?, what are the  procedures?, 
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how will data be collected, how many patients you will need?, and what is to be done in 
any eventuality? It specifies the standard operation procedure (SOP). It describes the back-
ground, objective(s), design, methodology, statistical considerations, and organization of 
the trial. It represents a guideline for the conduct, quality control of a clinical trial, and 
guidelines to the monitoring groups. It is considered as a legal document for regulatory 
bodies and may be used to procure funding. It should contain the right amount of detail 
necessary for the reader of each section to be able to understand exactly what is required to 
conduct the study [5].
6. Specific objectives
6.1. Primary objective
It defines one question the investigators are most interested in answering and is capable 
of being adequately answered. It should define the primary endpoint, which is a defined 
measurement or assessment. If possible, end-points need to be objective measurements 
rather than subjective outcomes. However, many diseases necessitate measurements of 
subjective symptoms, e.g., pain, discomfort, irritation, etc. Ideally, a clinical trial has just 
one end point, and this is the primary end point. Common failing is too many end points. 
The best designed trials keep it simple as this makes a clear answer more likely and easier 
to achieve.
6.2. Secondary objectives
Secondary objectives should be based on subgroup hypotheses that are respectively defined 
and based on reasonable expectations and should not distract from the primary objective.
Methods include hypothesis, patient population, inclusion criteria, exclusion criteria, and 
trial design.
Protocol amendment: A written description of a change(s) to or formal clarification of a pro-
tocol. Must be approved by IRB prior to implementation may be partial or complete.
7. Phases of clinical trials
Phase 0: Preclinical animal studies.
Phase I: First-time test of intervention in a small group of people (20–80) to evaluate safety, 
determine appropriate dosage, and identify side effects. Follows successful pharmacological 
and toxicological studies in animals start with 1/5th or 1/10th maximum tolerated dose in the 
most sensitive animal species.
Phase II: Intervention given to a larger group (100–300) to evaluate effectiveness and safety. 
First administered to patients. Phase IIa (early phase II) potential benefits and side effects 
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establish dose range for phase IIb. Phase IIb (late phase II) establishes efficacy in specific dis-
ease. Compare efficacy and side effects with other drugs for same conditions.
Phase III: Randomized, controlled, double-blinded. A sufficient sample size for statistical 
evaluation of efficacy and safety. Intervention given to large groups (1000–3000) to confirm 
effectiveness, monitor side effects, compare to other treatments, and collect information that 
will allow it to be used safely. Successful phase III trial leads to request permission to market 
new drug.
Phase IV: After drug obtained marketing license, post marketing studies determine addi-
tional information including risks, benefits, and optimal use of an intervention [6].
8. Ethical considerations
Every possible precaution should be taken to ensure the safety of research participants includ-
ing uncoerced and truly informed consent ensuring that the research staff conducts the study 
honestly and thoroughly.
8.1. Evolution of research ethics guidelines
1. Nuremburg “Doctor’s Trial”: 1946 in response to Nazi atrocities of using concentration 
camp prisoners for human experiments.
2. Nuremburg: 1947
3. UN Universal Declaration of Human Rights: 1948
4. Declaration of Helsinki: 1964
5. Belmont Report: 1979
6. International Ethical Guidelines for Biomedical Research (CIOMS): 1993 (Updated 2002)
The Declaration of Helsinki: A set of principles defining the standards that should apply to 
biomedical research worldwide. It remains the cornerstone ethical reference for global medi-
cal research. It is a statement of clinical principles to provide guidance to physicians and other 
participants in medical research involving human participants.
Informed consent: It is a process by which the participant voluntarily confirms the willing-
ness to participate in a particular clinical research trial, after having been informed of all 
aspects of the trial that are relevant to the subject’s decision to participate. It consists of two 
parts: a written information describing the clinical trial and a form which the subject signs 
to document that he/she has given consent to take part in the study and obtained from the 
participants in the study population after explaining them fully about the purpose, duration, 
required procedures, expectations, risks and benefits, adverse effects of the trial if any, par-
ticipants’ rights and compensation and/or treatment available to subject in the event of trial-
related injury. It is a process not just signing a form communication document not having a 
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legal binding on the patients. The consent should state that the subject’s participation is vol-
untary and that he/she may refuse to participate or withdraw from the trial at any time [5, 7].
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